Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study | Zendy

I Florescu | Zendy; Mircea Beuran | Zendy; R Dimov | Zendy; Artūras Razbadauskas | Zendy; Markian R. Bochan | Zendy; G Fichev | Zendy; Gary Dukart | Zendy; Timothy Babinchak | Zendy; C. Angel Cooper | Zendy; Evelyn J. EllisGrosse | Zendy; Nathalie Dartois | Zendy; Hassan Gandjini | Zendy

Open Access

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study

Author(s) -

I Florescu,

Mircea Beuran,

R Dimov,

Artūras Razbadauskas,

Markian R. Bochan,

G Fichev,

Gary Dukart,

Timothy Babinchak,

C. Angel Cooper,

Evelyn J. EllisGrosse,

Nathalie Dartois,

Hassan Gandjini

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn250

Subject(s) - tigecycline , medicine , linezolid , vancomycin , methicillin resistant staphylococcus aureus , population , surgery , enterococcus faecium , vancomycin resistant enterococcus , staphylococcus aureus , antibiotics , microbiology and biotechnology , genetics , bacteria , biology , environmental health

Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are causing serious nosocomial infections. Tigecycline was evaluated in hospitalized patients with MRSA or VRE infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research